Matches in Nanopublications for { ?s ?p "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 15 of
15
with 100 items per page.
- NP606157.RAQ4yc5nC76Fu7v8l9Nw_uHGN_rqpud43hEnQHl0zRsYQ130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606157.RAQ4yc5nC76Fu7v8l9Nw_uHGN_rqpud43hEnQHl0zRsYQ130_provenance.
- NP781588.RAVDJ5SbY4ez5LUK9MGkEsoNk-XwPSbNgvW-y1uT1eaEw130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781588.RAVDJ5SbY4ez5LUK9MGkEsoNk-XwPSbNgvW-y1uT1eaEw130_provenance.
- assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP512163.RAD5RnMq51dysxCGvZkxs-3rC9GNyp-ZSyJ80UNc4C47s130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512163.RAD5RnMq51dysxCGvZkxs-3rC9GNyp-ZSyJ80UNc4C47s130_provenance.
- NP512156.RAZLsMwyM3Lnh3ffdiTWtNHM82P9GwCc1SD22eN5yR2Q0130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512156.RAZLsMwyM3Lnh3ffdiTWtNHM82P9GwCc1SD22eN5yR2Q0130_provenance.
- NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512167.RAbfs5CaQLiFcbNjGIYZ7IPQ-YHvtdpuiXXwF9wBUAG0k130_provenance.
- assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP978678.RAuy1Cf_f8w9ojLgi-dFEfh0LOgL9hZBMjc2ATgBwMtHI130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978678.RAuy1Cf_f8w9ojLgi-dFEfh0LOgL9hZBMjc2ATgBwMtHI130_provenance.
- NP914207.RAGyiGXw7TrdOm9Xzr84UJ6FVJ4P9lWewTkPyWfMBOyoM130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914207.RAGyiGXw7TrdOm9Xzr84UJ6FVJ4P9lWewTkPyWfMBOyoM130_provenance.
- NP512164.RAO3fUc4D9yBSdr5e0QxdpW-ApdaylqT87GmoGYd3sjQA130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512164.RAO3fUc4D9yBSdr5e0QxdpW-ApdaylqT87GmoGYd3sjQA130_provenance.
- NP873320.RAG5PTIqr-PJtRGPUQZ5GGmlNkZgunYkeBY_DWREHHkEk130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873320.RAG5PTIqr-PJtRGPUQZ5GGmlNkZgunYkeBY_DWREHHkEk130_provenance.
- NP512168.RA60RWw-bJtPbncOrpODxziS1CEFKPpHcwgDsyKyBU4e0130_assertion description "[Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP512168.RA60RWw-bJtPbncOrpODxziS1CEFKPpHcwgDsyKyBU4e0130_provenance.